

**CRISPR Market by Offering [Product (Kits, Enzymes, Libraries), Service (gRNA Synthesis, Cell Line Development, Screening, Validation)], Application (Drug Discovery, Development, Agriculture) Competitive Landscape, Company Profiles
-Global Forecast to 2030**

Market Report | 2025-05-14 | 267 pages | MarketsandMarkets

AVAILABLE LICENSES:

- Single User \$4950.00
- Multi User \$6650.00
- Corporate License \$8150.00
- Enterprise Site License \$10000.00

Report description:

The global CRISPR market is anticipated to reach USD 5.47 billion by 2030 from USD 3.21 billion in 2025, at a significant CAGR of 11.2%.

The CRISPR market is experiencing substantial growth, with a notable CAGR driven by its increasing adoption in research, clinical, and industrial applications. Several factors contribute to this market expansion, including the rising prevalence of genetic disorders, the growing use of CRISPR in drug discovery and gene therapy, and increased investments in biotechnology research and development. Additionally, advancements in CRISPR tools, improved delivery systems, and supportive regulatory developments further accelerate its integration into mainstream research and therapeutic pipelines.

"Products dominated the CRISPR market, by offering, in 2024."

Based on offerings, the CRISPR market is categorized into two main segments: products and services. The products segment includes CRISPR kits & enzymes, CRISPR libraries, and other products. The services segment encompasses gRNA synthesis & cell line development, screening & validation, and other services.

Users are increasingly seeking ongoing innovations, new product releases, and access to standardized, ready-to-use kits. These products are widely utilized in academic, clinical, and industrial research for applications in genome editing, functional genomics, and therapeutic development. This is a key factor driving market growth.

"The drug discovery & development application segment is anticipated to grow at a faster pace during the forecast period."

The application segment is divided into three categories: drug discovery & development, agriculture, and other applications. The largest segment is drug discovery & development, as CRISPR technology enhances early-stage research by facilitating the

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

identification of connections between genes and diseases, as well as drug functions. This approach helps reduce timelines and increase the likelihood of success. Additionally, pharmaceutical & biotechnology companies are integrating CRISPR into their research and development processes to advance personalized medicine, gene therapy, and functional genomics, thereby enhancing the utilization of CRISPR technology.

"Pharmaceutical & biotechnology companies dominated the CRISPR products market, by end user, in 2024."

Based on end users, the CRISPR products market is segmented into pharmaceutical & biotechnology companies, academic & research institutes, and other end users. In 2024, pharmaceutical & biotechnology companies dominated this market. This dominance is driven by increasing investments in cell and gene therapies, as well as the demand for precise genetic tools for target identification and validation. These companies rely heavily on CRISPR technologies, and their strong financial capacity allows them to adopt advanced and customized CRISPR products at scale, further contributing to their significant market share.

"North America accounted for the largest share of the CRISPR market in 2024."

The market is divided by region into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. North America holds the largest share of the CRISPR market and is expected to maintain its lead. This dominance is attributed to the presence of prominent research institutions and significant investments in biotechnology. Additionally, the growing emphasis on cutting-edge medical research, personalized medicine, and precision medicine in the US gives North America a competitive advantage. The European CRISPR market is also experiencing steady growth, fueled by increased research and development efforts, particularly in countries such as Germany, the UK, and France.

In-depth interviews have been conducted with chief executive officers (CEOs), directors, and other executives from various key organizations operating in the CRISPR market.

The primary interviews conducted for this report can be categorized as follows:

-□By Respondent: Supply Side (70%) and Demand Side (30%)

-□By Designation: Managers (45%), CXOs & Directors (30%), and Executives (25%)

-□By Region: North America (35%), Europe (30%), Asia Pacific (25%), Latin America (5%), and the Middle East & Africa (5%)

The prominent players operating in the CRISPR market are Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), Agilent Technologies, Inc. (US), GenScript (US), Takara Bio (Japan), Creative Biogene (US), Fujian SunyBiotech Co., Ltd. (China), EditCo (US), Caribou Biosciences, Inc. (US), Lonza Group (Switzerland), Danaher Corporation (US), Revvity, Inc. (US), Hera BioLabs (US), OriGene Technologies, Inc. (US), Celecta, Inc. (US), Mammoth Biosciences, Inc. (US), Applied StemCell (US), New England Biolabs Inc. (US), ToolGen Inc. (South Korea), GeneCopoeia, Inc. (US), Twist Bioscience Corporation (US), Synthego Corporation (US), eGenesis (US), Inscripta, Inc. (US), and Precision BioSciences, Inc. (US), among others.

Research Coverage:

The CRISPR market report is segmented based on offerings [products (CRISPR kits & enzymes, CRISPR libraries, and other products), services (gRNA synthesis & cell line development, screening & validation, and other services)], applications (drug discovery & development, agriculture, and other applications), and end users [product (pharmaceutical & biotechnology companies, academic & research institutes, and other end users), and service (pharmaceutical & biotechnology companies, academic & research institutes, and other end users)].

The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the CRISPR market. A detailed analysis of the key industry players has been done to provide insights into their business overview, products, key strategies, collaborations, partnerships, and agreements. The report also covers new launches, collaborations, acquisitions, and recent developments associated with the CRISPR market.

Key Benefits of Buying the Report:

The report will assist both market leaders and new entrants by providing accurate revenue estimates for CRISPR and its subsegments. It will also help stakeholders better understand the competitive landscape, enabling them to position their businesses effectively and develop suitable go-to-market strategies. Additionally, this report will allow stakeholders to gauge the market dynamics and offer insights into the key drivers, restraints, opportunities, and challenges within the market.

The report provides insights into the following pointers:

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- Analysis of key drivers (growing demand for CRISPR-based gene therapies, advancements in CRISPR technology, and growing government and private investments and funding for CRISPR technology), restraints (technical challenges associated with CRISPR technology), opportunities (development of new vaccines and treatments for genetic diseases and expanding industrial and agricultural applications of CRISPR), and challenges (regulatory hurdles for CRISPR advancements) influencing the growth of the market.
- Product Development/Innovation: In-depth analysis of emerging technologies in CRISPR, R&D activities, and new product launches in the CRISPR market.
- Market Development: The report provides detailed information about profitable markets and analyzes the market conditions across various regions.
- Market Diversification: Comprehensive information about new products, unexplored regions, recent updates, and investments in the CRISPR market.
- Competitive Assessment: Comprehensive evaluation of market shares, growth strategies, and product & service offerings of leading companies such as Thermo Fisher Scientific Inc. (US), Agilent Technologies, Inc. (US), Merck KGaA (Germany), and GenScript (US).

Table of Contents:

1	INTRODUCTION	24
1.1	STUDY OBJECTIVES	24
1.2	MARKET DEFINITION	24
1.3	STUDY SCOPE	25
1.3.1	MARKETS COVERED & REGIONAL SCOPE	25
1.3.2	INCLUSIONS & EXCLUSIONS	26
1.3.3	YEARS CONSIDERED	26
1.3.4	CURRENCY CONSIDERED	27
1.4	STAKEHOLDERS	27
1.5	SUMMARY OF CHANGES	27
2	RESEARCH METHODOLOGY	29
2.1	RESEARCH DATA	29
2.1.1	SECONDARY DATA	29
2.1.2	PRIMARY RESEARCH	30
2.2	MARKET SIZE ESTIMATION	32
2.2.1	GLOBAL MARKET ESTIMATION	32
2.2.1.1	Insights From Primary Experts	35
2.2.2	SEGMENTAL MARKET ESTIMATION (TOP-DOWN APPROACH)	35
2.3	MARKET GROWTH RATE PROJECTION	37
2.4	DATA TRIANGULATION	38
2.5	RESEARCH ASSUMPTIONS	39
2.6	RESEARCH LIMITATIONS	40
2.7	RISK ANALYSIS	41
3	EXECUTIVE SUMMARY	42
4	PREMIUM INSIGHTS	45
4.1	CRISPR MARKET OVERVIEW	45
4.2	NORTH AMERICA: CRISPR MARKET, BY APPLICATION AND COUNTRY (2024)	46
4.3	CRISPR MARKET SHARE, BY END USER, 2025 VS. 2030	46
5	MARKET OVERVIEW	47
5.1	INTRODUCTION	47
5.2	MARKET DYNAMICS	47

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

5.2.1	DRIVERS	48
5.2.1.1	Growing demand for CRISPR-based gene therapies	48
5.2.1.2	Advancements in CRISPR technology	49
5.2.1.3	Growing government and private investments and funding for CRISPR technology	50
5.2.2	RESTRAINTS	51
5.2.2.1	Technical challenges associated with CRISPR technology	51
5.2.3	OPPORTUNITIES	51
5.2.3.1	Development of new vaccines and treatments for genetic diseases	51
5.2.3.2	Expanding industrial and agricultural applications of CRISPR	52
5.2.4	CHALLENGES	52
5.2.4.1	Regulatory hurdles for CRISPR advancements	52
5.2.5	TECHNOLOGY ANALYSIS	53
5.2.5.1	Key technologies	53
5.2.5.1.1	CRISPR-Cas systems	53
5.2.5.1.2	gRNA design & optimization	54
5.2.5.1.3	High-throughput CRISPR screening	54
5.2.5.2	Complementary technologies	54
5.2.5.2.1	Synthetic biology	54
5.2.5.2.2	Single-cell genomics	55
5.2.5.2.3	Next-generation sequencing	55
5.2.5.3	Adjacent technologies	55
5.2.5.3.1	Stem cell engineering	55
5.2.5.3.2	Synthetic DNA & gene synthesis	56
5.2.5.3.3	Microfluidics	56
5.3	TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES	57
5.4	SUPPLY CHAIN ANALYSIS	57
5.5	VALUE CHAIN ANALYSIS	59
5.6	ECOSYSTEM ANALYSIS	60
5.7	PORTER'S FIVE FORCES ANALYSIS	62
5.7.1	THREAT OF NEW ENTRANTS	63
5.7.2	THREAT OF SUBSTITUTES	63
5.7.3	BARGAINING POWER OF BUYERS	63
5.7.4	BARGAINING POWER OF SUPPLIERS	64
5.7.5	INTENSITY OF COMPETITIVE RIVALRY	64
5.8	REGULATORY ANALYSIS	65
5.8.1	REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS	65
5.8.2	REGULATORY FRAMEWORK	70
5.8.2.1	North America	70
5.8.2.1.1	US	70
5.8.2.1.2	Canada	70
5.8.2.2	Europe	70
5.8.2.2.1	Germany	70
5.8.2.2.2	UK	70
5.8.2.2.3	France	71
5.8.2.3	Asia Pacific	71

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

5.8.2.3.1	Japan	71
5.8.2.3.2	China	71
5.8.2.4	Latin America	71
5.8.2.4.1	Brazil	71
5.8.2.5	Middle East & Africa	72
5.8.2.5.1	GCC Countries	72
5.8.2.5.2	South Africa	72
5.9	PRICING ANALYSIS	72
5.9.1	AVERAGE SELLING PRICE OF KITS AND REAGENTS, BY KEY PLAYER (2024)	73
5.9.2	AVERAGE SELLING PRICE TREND OF CRISPR KITS & REAGENTS, BY KEY PLAYER, 2022-2024	73
5.9.3	INDICATIVE PRICE TREND FOR CRISPR SERVICES	74
5.9.4	AVERAGE SELLING PRICE TREND OF CRISPR KITS AND REAGENTS, BY REGION, 2024	75
5.10	PATENT ANALYSIS	76
5.11	KEY CONFERENCES & EVENTS, 2025-2026	78
5.12	KEY STAKEHOLDERS & BUYING CRITERIA	79
5.12.1	KEY STAKEHOLDERS IN BUYING PROCESS	79
5.12.2	CRISPR MARKET: BUYING CRITERIA	80
5.13	INVESTMENT & FUNDING SCENARIO	81
5.14	IMPACT OF AI ON CRISPR MARKET	81
5.15	TRADE ANALYSIS	83
5.15.1	IMPORT DATA FOR KITS & REAGENTS, 2019-2023	83
5.15.2	EXPORT DATA FOR KITS & REAGENTS, 2019-2023	84
5.15.3	TRUMP IMPACT OVERVIEW: CRISPR MARKET	84
5.15.3.1	Introduction	84
5.15.3.2	Key tariff rates	85
5.15.3.3	Price impact analysis	86
5.15.3.4	Key Impact on various regions	87
5.15.3.4.1	US	87
5.15.3.4.2	Europe	87
5.15.3.4.3	Asia Pacific	88
5.15.3.4.4	Rest of the World	88
5.15.3.5	End-use industry impact	88
5.15.3.5.1	Pharmaceutical & biotech companies	89
5.15.3.5.2	Contract research organizations (CROs)	89
5.15.3.5.3	Academic & research institutes	89
6	CRISPR MARKET, BY OFFERING	90
6.1	INTRODUCTION	91
6.2	PRODUCTS	91
6.2.1	ADVANCEMENTS IN GENOME EDITING TO DRIVE GROWTH	91
6.3	SERVICES	93
6.3.1	GROWING DEMAND FOR PRECISE GENOME EDITING TOOLS IN RESEARCH AND CLINICAL APPLICATIONS TO BOOST MARKET	93
7	CRISPR PRODUCTS MARKET, BY TYPE	96
7.1	INTRODUCTION	97
7.2	CRISPR KITS & ENZYMES	97

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

7.2.1	CRISPR KITS & ENZYMES SEGMENT TO DOMINATE CRISPR PRODUCTS MARKET DURING FORECAST PERIOD	97
7.3	CRISPR LIBRARIES	99
7.3.1	INCREASING APPLICATIONS OF CRISPR LIBRARIES IN GENE EDITING TO DRIVE GROWTH	99
7.4	OTHER PRODUCTS	101
8	CRISPR PRODUCTS MARKET, BY END USER	104
8.1	INTRODUCTION	105
8.2	PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES	105
8.2.1	INCREASING PRODUCT APPROVALS AND ROBUST CLINICAL PIPELINE TO PROPEL MARKET	105
8.3	ACADEMIC & RESEARCH INSTITUTES	108
8.3.1	INCREASING FUNDING FOR GENOMIC PROJECTS TO PROPEL MARKET	108
8.4	OTHER END USERS	110
9	CRISPR MARKET, BY SERVICE	112
9.1	INTRODUCTION	113
9.1.1	GRNA SYNTHESIS & CELL LINE DEVELOPMENT	113
9.1.1.1	Emerging opportunities in CRISPR gRNA synthesis & cell line development to drive growth	113
9.1.2	SCREENING & VALIDATION	115
9.1.2.1	Rapid advancements in CRISPR technology to drive growth	115
9.2	OTHER SERVICES	118
10	CRISPR SERVICES MARKET, BY END USER	120
10.1	INTRODUCTION	121
10.2	PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES	121
10.2.1	ADVANCEMENTS IN GENOME EDITING TO DRIVE GROWTH	121
10.3	ACADEMIC & RESEARCH INSTITUTES	123
10.3.1	INCREASING INVESTMENTS IN GENOMIC PROJECTS TO PROPEL MARKET	123
10.4	OTHER END USERS	126
11	CRISPR MARKET, BY APPLICATION	128
11.1	INTRODUCTION	129
11.2	DRUG DISCOVERY & DEVELOPMENT	129
11.2.1	ADVANCEMENTS IN GENOME EDITING TO DRIVE GROWTH	129
11.3	AGRICULTURE	132
11.3.1	GROWING DEMAND FOR ENHANCED CROP TRAITS TO DRIVE GROWTH	132
11.4	OTHER APPLICATIONS	134
12	CRISPR MARKET, BY REGION	136
12.1	INTRODUCTION	137
12.2	NORTH AMERICA	137
12.2.1	MACROECONOMIC OUTLOOK OF NORTH AMERICA	138
12.2.2	US	141
12.2.2.1	Increasing demand for CRISPR products and services across various industries to drive growth	141
12.2.3	CANADA	144
12.2.3.1	Increasing demand for gene-editing technologies to boost growth	144
12.3	EUROPE	146
12.3.1	MACROECONOMIC OUTLOOK OF EUROPE	146
12.3.2	GERMANY	150
12.3.2.1	Rapidly increasing biotechnology sector to support growth	150
12.3.3	UK	152

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

12.3.3.1	Significant government investments in genomics research to propel growth	152
12.3.4	FRANCE	155
12.3.4.1	Increasing demand for targeted therapies and personalized medicine to propel growth	155
12.3.5	ITALY	157
12.3.5.1	Increasing demand for innovative therapeutic solutions to drive growth	157
12.3.6	SPAIN	160
12.3.6.1	Increasing demand for precision medicine to drive growth	160
12.3.7	REST OF EUROPE	162
12.4	ASIA PACIFIC	164
12.4.1	MACROECONOMIC OUTLOOK FOR ASIA PACIFIC	164
12.4.2	CHINA	169
12.4.2.1	Increasing investments in R&D to drive growth	169
12.4.3	JAPAN	171
12.4.3.1	Potential of CRISPR-based therapies in personalized medicine to present opportunities for market growth	171
12.4.4	INDIA	174
12.4.4.1	Increasing prevalence of genetic disorders to support growth	174
12.4.5	REST OF ASIA PACIFIC	176
12.5	LATIN AMERICA	179
12.5.1	MACROECONOMIC OUTLOOK FOR LATIN AMERICA	179
12.5.2	BRAZIL	182
12.5.2.1	Growing adoption of genome technologies to propel growth	182
12.5.3	REST OF LATIN AMERICA	184
12.6	MIDDLE EAST & AFRICA	186
12.6.1	MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA	186
13	COMPETITIVE LANDSCAPE	190
13.1	INTRODUCTION	190
13.2	KEY PLAYER STRATEGY/RIGHT TO WIN	190
13.2.1	OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN CRISPR MARKET	191
13.3	REVENUE ANALYSIS, 2020?2024	192
13.4	MARKET SHARE ANALYSIS, 2024	192
13.5	COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024	194
13.5.1	STARS	194
13.5.2	EMERGING LEADERS	194
13.5.3	PERVASIVE PLAYERS	195
13.5.4	PARTICIPANTS	195
13.5.5	COMPANY FOOTPRINT: KEY PLAYERS, 2024	196
13.5.5.1	Company footprint	196
13.5.5.2	Region footprint	197
13.5.5.3	Product footprint	197
13.5.5.4	Service footprint	198
13.5.5.5	Application footprint	199
13.6	COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024	199
13.6.1	PROGRESSIVE COMPANIES	199
13.6.2	RESPONSIVE COMPANIES	199
13.6.3	DYNAMIC COMPANIES	200
13.6.4	STARTING BLOCKS	200
13.6.5	COMPETITIVE BENCHMARKING: STARTUPS/SMES	201

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

13.6.5.1	Detailed list of key startups/SMEs	201
13.6.5.2	Competitive benchmarking of key startups/SMEs	202
13.7	COMPETITIVE SCENARIO	203
13.7.1	PRODUCT LAUNCHES & APPROVALS	203
13.7.2	DEALS	204
13.7.3	EXPANSIONS	205
13.8	COMPANY VALUATION & FINANCIAL METRICS	206
13.9	BRAND/PRODUCT COMPARISON	207
14	COMPANY PROFILES	208
14.1	KEY PLAYERS	208
14.1.1	THERMO FISHER SCIENTIFIC INC.	208
14.1.1.1	Business overview	208
14.1.1.2	Products/Services offered	209
14.1.1.3	Recent developments	211
14.1.1.3.1	Product/Service launches	211
14.1.1.3.2	Deals	211
14.1.1.3.3	Expansions	212
14.1.1.4	MnM view	212
14.1.1.4.1	Key strengths	212
14.1.1.4.2	Strategic choices	213
14.1.1.4.3	Weaknesses & competitive threats	213
14.1.2	MERCK KGAA	214
14.1.2.1	Business overview	214
14.1.2.2	Products/Services offered	215
14.1.2.3	Recent developments	216
14.1.2.3.1	Deals	216
14.1.2.4	MnM view	217
14.1.2.4.1	Key strengths	217
14.1.2.4.2	Strategic choices	217
14.1.2.4.3	Weaknesses & competitive threats	217
14.1.3	AGILENT TECHNOLOGIES, INC.	218
14.1.3.1	Business overview	218
14.1.3.2	Products/Services offered	219
14.1.3.3	Recent developments	220
14.1.3.3.1	Deals	220
14.1.3.3.2	Expansions	221
14.1.3.4	MnM view	221
14.1.3.4.1	Key strengths	221
14.1.3.4.2	Strategic choices	221
14.1.3.4.3	Weaknesses & competitive threats	221
14.1.4	GENSCRIPT	222
14.1.4.1	Business overview	222
14.1.4.2	Products/Services offered	223
14.1.4.3	Recent developments	225
14.1.4.3.1	Product/service approvals/launches	225
14.1.4.3.2	Deals	225

- 14.1.4.3.3 Expansions 226
- 14.1.5 REVVITY 227
 - 14.1.5.1 Business overview 227
 - 14.1.5.2 Products/Services offered 228
 - 14.1.5.3 Recent developments 230
 - 14.1.5.3.1 Deals 230
- 14.1.6 LONZA 231
 - 14.1.6.1 Business overview 231
 - 14.1.6.2 Products/Services offered 232
 - 14.1.6.3 Recent developments 233
 - 14.1.6.3.1 Deals 233
- 14.1.7 DANAHER CORPORATION 234
 - 14.1.7.1 Business overview 234
 - 14.1.7.2 Products/Services offered 235
 - 14.1.7.3 Recent developments 236
 - 14.1.7.3.1 Deals 236
- 14.1.8 TAKARA BIO INC. 237
 - 14.1.8.1 Business overview 237
 - 14.1.8.2 Products/Services offered 238
 - 14.1.8.3 Recent developments 239
 - 14.1.8.3.1 Deals 239
- 14.1.9 CREATIVE BIOGENE 240
 - 14.1.9.1 Business overview 240
 - 14.1.9.2 Products/Services offered 240
 - 14.1.9.3 Recent developments 241
 - 14.1.9.3.1 Product/service approvals/launches 241
- 14.1.10 FUJIAN SUNYBIOTECH CO., LTD. 242
 - 14.1.10.1 Business overview 242
 - 14.1.10.2 Products/Services offered 242
- 14.1.11 EDITCO 243
 - 14.1.11.1 Business overview 243
 - 14.1.11.2 Products/Services offered 243
 - 14.1.11.3 Recent financials 244
 - 14.1.11.3.1 Deals 244
- 14.1.12 CARIBOU BIOSCIENCES, INC. 245
 - 14.1.12.1 Business overview 245
 - 14.1.12.2 Products/Services offered 246
 - 14.1.12.3 Recent developments 246
 - 14.1.12.3.1 Deals 246
- 14.1.13 HERA BIOLABS 247
 - 14.1.13.1 Business overview 247
 - 14.1.13.2 Products/Services offered 247
- 14.1.14 ORIGENE TECHNOLOGIES, INC. 248
 - 14.1.14.1 Business overview 248
 - 14.1.14.2 Products/Services offered 248
- ?
- 14.1.15 CELLECTA, INC. 249

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

14.1.15.1	Business overview	249
14.1.15.2	Products/Services offered	249
14.2	OTHER PLAYERS	251
14.2.1	MAMMOTH BIOSCIENCES, INC.	251
14.2.2	APPLIED STEMCELL	251
14.2.3	NEW ENGLAND BIOLABS	252
14.2.4	TOOLGEN, INC.	253
14.2.5	GENECOPOEIA, INC.	254
14.2.6	TWIST BIOSCIENCE	255
14.2.7	SYNTHEGO	256
14.2.8	EGENESIS	257
14.2.9	INSCRIPTA, INC.	257
14.2.10	PRECISION BIOSCIENCES	258
15	APPENDIX	259
15.1	DISCUSSION GUIDE	259
15.2	KNOWLEDGESTORE: MARKETSandMARKETS' SUBSCRIPTION PORTAL	262
15.3	CUSTOMIZATION OPTIONS	264
15.4	RELATED REPORTS	265
15.5	AUTHOR DETAILS	266

**CRISPR Market by Offering [Product (Kits, Enzymes, Libraries), Service (gRNA Synthesis, Cell Line Development, Screening, Validation)], Application (Drug Discovery, Development, Agriculture) Competitive Landscape, Company Profiles
-Global Forecast to 2030**

Market Report | 2025-05-14 | 267 pages | MarketsandMarkets

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User	\$4950.00
	Multi User	\$6650.00
	Corporate License	\$8150.00
	Enterprise Site License	\$10000.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Zip Code*

Country*

Date

Signature